Closed
The Marked Chart Wire · Health
Enhertu
AstraZeneca paid a $75 million milestone to Daiichi Sankyo following European Union approval of the therapy for early-stage HER2-positive breast cancer. Trial results showed a 53 percent reduction in recurrence or death risk compared to T-DM1.
Prices from Before the open · based on Mon close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
PACIFIC-9
AstraZeneca updated the timeline for its PACIFIC-9 phase 3 trial in non-small cell lung cancer, moving the data readout from the second half of 2026 to the first half of 2027. Enrollment for the study is complete.
AstraZeneca ADCs
AstraZeneca will seek approval for sonesitatug vedotin after a trial showed a 42 percent reduction in death risk for gastric cancer patients. The company projects peak annual sales of $3 billion to $5 billion for the drug.
Lung Cancer
Amgen reported that adding its medication to AstraZeneca’s immunotherapy reduced the chance of death by 58 percent for individuals with advanced lung tumors.
Weight-Loss Drugs
A court rejected Novo Nordisk's legal effort to stop Eli Lilly from advertising its weight-loss medications, clearing the way for the company to continue its marketing campaign.
Bristol Myers Squibb
Bristol Myers Squibb announced that its cancer treatment doubled the time patients lived without disease progression. The drug also showed promising results in other solid tumors.
Moderna
The biotech executive stated that the current melanoma vaccine is anticipated to show efficacy against additional types of malignancy.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.